13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001831942
Total reported value
$1.7B
$1.7B
37 檔
45.4%
During the Q3 2025 filing period, Commodore Capital LP (CIK: 0001831942) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $1.7B across 37 reported positions.
In Q3 2025, Commodore Capital LP displayed an active expansion posture, initiating 14 new positions and adding to 10 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Merus N V | Stock-Other | 16.20% | — | — | |
| 2 | NUVL | Nuvalent Inc-a | Stock-Other | 5.91% | -4.20% | +1.82% | |
| 3 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 5.29% | -2.78% | EXIT | |
| 4 | COGT | Cogent Biosciences Inc | Stock-Other | 5.08% | +0.60% | +213.69% | |
| 5 | ELVN | Enliven Therapeutics Inc | Stock-Other | 4.69% | +2.47% | — | |
| 6 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 4.58% | — | +0.57% | |
| 7 | ALKS | Alkermes plc | Stock-Healthcare | 4.54% | +0.77% | +26.40% | |
| 8 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 4.46% | -1.26% | EXIT | |
| 9 | RLAY | Relay Therapeutics Inc | Stock-Other | 4.33% | +3.58% | +27.34% | |
| 10 | CLDX | Celldex Therapeutics Inc | Stock-Other | 3.82% | -1.96% | -12.22% | |
| 11 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 3.37% | — | -13.59% | |
| 12 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.37% | — | -34.36% | |
| 13 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 3.32% | — | -4.65% | |
| 14 | PHVS | Pharvaris N.V. | Stock-Other | 2.95% | -0.21% | +26.53% | |
| 15 | CDTX | Cidara Therapeutics Inc | Stock-Other | 2.73% | — | -50.21% | |
| 16 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 2.70% | +1.50% | — | |
| 17 | TYRA | Tyra Biosciences Inc | Stock-Other | 2.30% | -1.91% | +8.87% | |
| 18 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 2.09% | — | — | |
| 19 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.07% | -1.90% | — | |
| 20 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 1.86% | — | -35.50% | |
| 21 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.71% | -2.04% | EXIT | |
| 22 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.65% | — | +23.48% | |
| 23 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.63% | -1.10% | — | |
| 24 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 1.48% | — | — | |
| 25 | ASMB | Assembly Biosciences Inc | Stock-Other | 1.25% | +0.71% | — | |
| 26 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 1.20% | — | — | |
| 27 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 1.16% | +0.76% | — | |
| 28 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.62% | +4.19% | NEW | |
| 29 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.56% | — | — | |
| 30 | PEPG | Pepgen Inc | Stock-Other | 0.53% | +0.02% | — | |
| 31 | ENTA | Enanta Pharmaceuticals Inc | Stock-Other | 0.47% | — | — | |
| 32 | SABS | Sab Biotherapeutics Inc | Stock-Other | 0.43% | -0.31% | — | |
| 33 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 0.43% | +0.13% | — | |
| 34 | ✓ | Stock-Other | 0.39% | — | — | ||
| 35 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.30% | +0.70% | — | |
| 36 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.27% | +0.04% | NEW | |
| 37 | ✓ | Crescent Biopharma Inc. | Stock-Other | 0.26% | — | -0.63% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ✓ | Merus N V | +2.3% | — | Trim |
| 2 | TYRA | Tyra Biosciences Inc | +1.7% | +8.87% | Add |
| 3 | COGT | Cogent Biosciences Inc | +1.2% | +213.69% | Trim |
| 4 | 260 | Centessa Pharmaceuticals-adr | +0.9% | -13.59% | Add |
| 5 | PHVS | Pharvaris N.V. | +0.7% | +26.53% | Add |
| 6 | ORKA | Oruka Therapeutics Inc | +0.6% | +23.48% | Add |
| 7 | DRUG | Bright Minds Biosciences Inc | +0.2% | — | Unchanged |
| 8 | AVTX | Avalo Therapeutics Inc | 0% | — | Unchanged |
| 9 | VTGN | Vistagen Therapeutics Inc | 0% | — | Unchanged |
| 10 | BRD1EUR | Mind Medicine Mindmed Inc | -0.1% | -35.50% | Trim |
| 11 | AGIO | Agios Pharmaceuticals Inc | -0.1% | +0.57% | Add |
| 12 | ✓ | -0.2% | — | Unchanged | |
| 13 | ALKS | Alkermes plc | -0.2% | +26.40% | Add |
| 14 | VRDN | Viridian Therapeutics Inc | -0.2% | -34.36% | Trim |
| 15 | APGE | Apogee Therapeutics Inc | -0.2% | — | Unchanged |
| 16 | IKT | Inhibikase Therapeutics Inc | -0.4% | — | Add |
| 17 | XENE | Xenon Pharmaceuticals Inc | -0.5% | -10.74% | Add |
| 18 | CLDX | Celldex Therapeutics Inc | -0.5% | -12.22% | Trim |
| 19 | SYRE | Spyre Therapeutics Inc | -0.7% | — | Unchanged |
| 20 | SLNOEUR | Soleno Therapeutics Inc | -1.6% | +121.31% | Add |
| 21 | NRIX | Nurix Therapeutics Inc | -1.8% | -4.27% | Trim |
| 22 | ELVN | Enliven Therapeutics Inc | -2.1% | — | Add |
| 23 | NUVL | Nuvalent Inc-a | -3.8% | +1.82% | Trim |
| 24 | RLAY | Relay Therapeutics Inc | — | NEW | New buy |
| 25 | PTGX | Protagonist Therapeutics Inc | — | NEW | New buy |
| 26 | PCVX | Vaxcyte Inc | — | EXIT | Sold out |
| 27 | VERA | Vera Therapeutics Inc | — | EXIT | Sold out |
| 28 | SRRK | Scholar Rock Holding CORP | — | EXIT | Sold out |
| 29 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 30 | AMLX | Amylyx Pharmaceuticals Inc | — | NEW | New buy |
| 31 | 430 | Terns Pharmaceuticals Inc | — | NEW | New buy |
| 32 | KYMR | Kymera Therapeutics Inc | — | NEW | New buy |
| 33 | ASMB | Assembly Biosciences Inc | — | NEW | New buy |
| 34 | CTMX | Cytomx Therapeutics Inc | — | NEW | New buy |
| 35 | LBRX | Lb Pharmaceuticals Inc | — | NEW | New buy |
| 36 | SLDB | Solid Biosciences Inc | — | EXIT | Sold out |
| 37 | CRDF | Cardiff Oncology Inc | — | EXIT | Sold out |
| 38 | TNGX | Tango Therapeutics Inc | — | NEW | New buy |
| 39 | ORIC | Oric Pharmaceuticals Inc | — | EXIT | Sold out |
| 40 | PEPG | Pepgen Inc | — | NEW | New buy |
| 41 | NGNE | Neurogene Inc | — | EXIT | Sold out |
| 42 | ENTA | Enanta Pharmaceuticals Inc | — | NEW | New buy |
| 43 | SABS | Sab Biotherapeutics Inc | — | NEW | New buy |
| 44 | CELC | Celcuity Inc | — | EXIT | Sold out |
| 45 | ✓ | Crescent Biopharma Inc. | — | NEW | New buy |
According to official SEC Form 13F filings, Commodore Capital LP reported a total U.S. public equity portfolio value of $1.7B across 37 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MERUS N V, NUVL, XENE) accounted for 45.4% of total reported equity market value during Q3 2025.
Top New Position Initiated
RLAY
市值: $88.7M
Top Position Liquidated / Trimmed
PCVX
前期市值: $62.3M
During Q3 2025, Commodore Capital LP's top holdings by market value included MERUS N V (16.2%)、NUVL (5.9%)、XENE (5.3%). The largest single position, MERUS N V, represented 16.2% of total portfolio value.
In Q3 2025, Commodore Capital LP made 39 total portfolio adjustments, initiating 14 new buys, adding to 10 positions, trimming 7 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.